Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer-Reference-Cited by-同舟云学术

Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer

Published:2023-03 Issue: Volume:170 Page:300-308
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Herzog Thomas J.,Pignata Sandro,Ghamande Sharad A.,Rubio Maria-Jesús,Fujiwara Keiichi,Vulsteke Christof,Armstrong Deborah K.,Sehouli Jalid,Coleman Robert L.,Gabra Hani,Scambia Giovanni,Monk Bradley J.,Arranz José A.,Ushijima Kimio,Hanna Rabbie,Zamagni Claudio,Wenham Robert M.,González-Martín Antionio,Slomovitz Brian,Jia Yan,Ramsay Lisa,Tewari Krishnansu S.,Weil Susan C.,Vergote Ignace B.

Funder

Eisai Incorporated

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Oncology

Reference29 articles.

1. Role of the folate receptor in ovarian cancer treatment: evidence mechanism, and clinical implications;Vergote;Cancer Metastasis Rev.,2015

2. Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay;Parker;Anal. Biochem.,2005

3. Overexpression of folate binding protein in ovarian cancers;Toffoli;Int. J. Cancer,1997

4. Expression of folate receptor-α (FRA) in gynecologic malignancies and its relationship to the tumor type;O’Shannessy;Int. J. Gynecol. Pathol.,2013

5. Serous ovarian carcinoma patients with high alpha-folate receptor had reducing survival and cytotoxic chemo-response;Chen;Mol. Oncol.,2012

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Generic semi-automated radiofluorination strategy for single domain antibodies: [18F]FB-labelled single domain antibodies for PET imaging of fibroblast activation protein-α or folate receptor-α overexpression in cancer;EJNMMI Radiopharmacy and Chemistry;2024-07-24

2. Generic semi-automated radiofluorination strategy for single domain antibodies: [18F]FB-labelled single domain antibodies for PET imaging of Fibroblast Activation Protein-α or Folate Receptor-α overexpression in cancer;2024-07-08

3. New hopes and promises in the treatment of ovarian cancer focusing on targeted treatment—a narrative review;Frontiers in Pharmacology;2024-06-14

4. Paradigm Shift: A Comprehensive Review of Ovarian Cancer Management in an Era of Advancements;International Journal of Molecular Sciences;2024-02-03

5. Future theranostic strategies: emerging ovarian cancer biomarkers to bridge the gap between diagnosis and treatment;Frontiers in Drug Delivery;2024-02-01